Cresco Labs (OTCMKTS:CRLBF) Upgraded to “Strong-Buy” by Roth Capital

Roth Capital upgraded shares of Cresco Labs (OTCMKTS:CRLBF) from a hold rating to a strong-buy rating in a research report sent to investors on Friday, Zacks.com reports. Roth Capital also issued estimates for Cresco Labs’ Q4 2024 earnings at $0.01 EPS and FY2025 earnings at $0.03 EPS.

CRLBF has been the topic of several other research reports. Wedbush upped their target price on Cresco Labs from $2.50 to $3.00 and gave the company an outperform rating in a research report on Thursday, May 16th. Needham & Company LLC reiterated a hold rating on shares of Cresco Labs in a research report on Thursday, May 16th. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $2.63.

Cresco Labs Price Performance

OTCMKTS:CRLBF opened at $1.73 on Friday. The stock has a market capitalization of $842.82 million, a PE ratio of -3.32 and a beta of 1.86. Cresco Labs has a 1-year low of $1.00 and a 1-year high of $2.77. The firm has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $1.88. The company has a current ratio of 1.36, a quick ratio of 0.89 and a debt-to-equity ratio of 1.57.

Cresco Labs (OTCMKTS:CRLBF) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.15). Cresco Labs had a negative return on equity of 6.78% and a negative net margin of 20.32%. The business had revenue of $184.36 million for the quarter, compared to analyst estimates of $184.26 million. On average, research analysts expect that Cresco Labs will post -0.03 EPS for the current fiscal year.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.